<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002166</url>
  </required_header>
  <id_info>
    <org_study_id>200D</org_study_id>
    <secondary_id>1100.859</secondary_id>
    <nct_id>NCT00002166</nct_id>
  </id_info>
  <brief_title>An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease</brief_title>
  <official_title>An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To provide access to Viramune and to evaluate the tolerance and safety of Viramune in
      patients with progressive, symptomatic HIV disease who failed or are intolerant to currently
      approved treatment for HIV-1 infection and who are unable to participate in another Viramune
      controlled clinical trial and have a compelling need for anti-HIV treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible adult patients (&gt;= 13 years of age) will receive treatment with Viramune once daily
      for 2 weeks and then twice daily. Eligible pediatric patients (&lt; 13 years of age) will
      receive a lower dose of Viramune once daily for 2 weeks and then twice daily. All patients
      will receive Viramune with or without concomitant antiretroviral therapy. Patients will be
      evaluated at weeks 2, 4, 8, 16, 24, 32 and every 8 weeks thereafter.

      PER AMENDMENT 01/31/97: Enrollment closed to adult patients. As of 1/31/97 only enrolling
      pediatric patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients must have:

          -  Patients &gt; 18 months of age with history of positive serology for HIV-1 infection or
             patients &lt;= 18 months of age with history of positive viral culture, detectable p24
             antigen, or positive peripheral blood mononuclear cell macro culture.

          -  Patients &gt;= 13 years of age with a CD4+ cell count &lt;= 200 cells/mm3. Patients &lt; 13
             years of age with a CD4% &lt;= 14% or a 50% decrease in CD4% in the past 6 months if the
             previous CD4% was &gt;=20%.

          -  Patient has failed or is intolerant to currently approved treatments for HIV-1
             infection and is unable to participate in a controlled viramune clinical trial.

          -  Written and informed consent from a parent or guardian for patients &lt; 18 years of age.

          -  Patient or guardian is willing and able to follow protocol requirements. (PER
             AMENDMENT 1/29/97:

          -  Enrollment is closed to adults, as of Jan. 29th only pediatric patients will be
             enrolled.)

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms and conditions are excluded:

        Patient qualifies for participation in an actively accruing Viramune controlled clinical
        trial.

        Concurrent Medication:

        Excluded:

          -  Dicumarol, Warfarin, and other anticoagulant medications.

          -  Tolbutamide.

          -  Investigational drugs, all protease inhibitors, and all other non-nucleoside
             transcriptase inhibitors.

          -  Neurotoxic drugs.

          -  Cimetidine.

          -  Erythromycin.

        Required:

        Patient has failed or is intolerant to currently approved treatments for HIV-1 infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Boehringer Ingelheim Pharmaceuticals Inc</name>
      <address>
        <city>Ridgefield</city>
        <state>Connecticut</state>
        <zip>06877</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2002</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Nevirapine</keyword>
  <keyword>Reverse Transcriptase Inhibitors</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

